Neoadjuvant Chemoimmunotherapy for Lung Cancer – A Meta-Analysis
1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant chemoimmunotherapy to neoadjuvant chemotherapy. 2. Both groups ...
Tag: peri-operative immunotherapy
The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer
1. At 24 months, more participants in the pembrolizumab group were alive without an event, compared with the placebo group. ...
Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
1. The pathological complete response rate for the experimental group was improved compared to the control group. 2. Progression-free survival ...